BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8865128)

  • 1. Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial.
    Comella P; Frasci G; Panza N; De Cataldis G; Cioffi R; Curcio C; Nicolella D; Micillo E; Ianniello GP; Biondi E; Perchard J; Comella G
    Lung Cancer; 1996 Aug; 15(1):103-14. PubMed ID: 8865128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
    Crinò L; Clerici M; Figoli F; Barduagni M; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F
    Lung Cancer; 1995 Apr; 12 Suppl 1():S125-32. PubMed ID: 7551920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
    Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
    Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
    Jelić S; Mitrović L; Radosavljević D; Elezar E; Babović N; Kovcin V; Tomasević Z; Kovacević S; Gavrilović D; Radulović S
    Lung Cancer; 2001 Oct; 34(1):1-13. PubMed ID: 11557107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
    Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
    Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of a carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer.
    Nakano H; Tsuchiya S; Takei Y; Minato K; Watanabe S; Makimoto T; Naruse I; Nomoto T; Ishihara S; Takise A; Ezawa K; Fueki N; Hoshino H; Saito R; Mori M
    Am J Clin Oncol; 1996 Jun; 19(3):245-8. PubMed ID: 8638534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
    White SC; Anderson H; Jayson GC; Ashcroft L; Ranson M; Thatcher N
    Ann Oncol; 2000 Feb; 11(2):201-6. PubMed ID: 10761756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
    Sculier JP; Klastersky J; Giner V; Bureau G; Thiriaux J; Dabouis G; Efremidis A; Ries F; Berchier MC; Sergysels R
    J Clin Oncol; 1994 Feb; 12(2):353-9. PubMed ID: 8113843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
    J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
    Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer.
    Makimoto T; Tsuchiya S; Nakano H; Watanabe S; Minato K; Takise A; Ezawa K; Fueki N; Naruse I; Nomoto T; Takei Y; Ishihara S; Mori M; Saitoh R
    Am J Clin Oncol; 1997 Feb; 20(1):51-4. PubMed ID: 9020288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
    Belani CP; Lee JS; Socinski MA; Robert F; Waterhouse D; Rowland K; Ansari R; Lilenbaum R; Natale RB
    Ann Oncol; 2005 Jul; 16(7):1069-75. PubMed ID: 15860487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
    Frasci G; Perillo G; Comella G; Comella P; Polverino M; Menzella G; Persico G
    Cancer; 1995 Apr; 75(7):1578-85. PubMed ID: 8826913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
    Klastersky J; Sculier JP; Lacroix H; Dabouis G; Bureau G; Libert P; Richez M; Ravez P; Vandermoten G; Thiriaux J
    J Clin Oncol; 1990 Sep; 8(9):1556-62. PubMed ID: 2167953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An early phase II trial combining cisplatin, carboplatin and vindesine in patients with inoperable non-small cell lung cancer].
    Haneda H; Koizumi M; Hayashi T
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):227-31. PubMed ID: 10700892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.